Influence of CYP2D6 and CYP2C19 Gene Variants on Antidepressant

Total Page:16

File Type:pdf, Size:1020Kb

Influence of CYP2D6 and CYP2C19 Gene Variants on Antidepressant The Pharmacogenomics Journal (2014) 14, 176–181 & 2014 Macmillan Publishers Limited All rights reserved 1470-269X/14 www.nature.com/tpj ORIGINAL ARTICLE Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder EJ Brandl1,2, AK Tiwari1,2, X Zhou2,3, J Deluce2,3, JL Kennedy1,2,DJMu¨ ller1,2,4 and MA Richter1,2,3,4 Numerous studies have reported on pharmacogenetics of antidepressant response in depression. In contrast, little is known of response predictors in obsessive-compulsive disorder (OCD), a disorder with among the lowest proportion of responders to medication (40–60%). Our study is the largest investigation to date (N ¼ 184) of treatment response and side effects to antidepressants in OCD based on metabolizer status for CYP2D6 and CYP2C19. We observed significantly more failed medication trials in CYP2D6 non-extensive compared with extensive metabolizers (P ¼ 0.007). CYP2D6 metabolizer status was associated with side effects to venlafaxine (P ¼ 0.022). There were nonsignificant trends for association of CYP2D6 metabolizer status with response to fluoxetine (P ¼ 0.056) and of CYP2C19 metabolizer status with response to sertraline (P ¼ 0.064). Our study is the first to indicate that CYP genes may have a role in antidepressant response in OCD. More research is required for a future clinical application of genetic testing, which could lead to improved treatment outcomes. The Pharmacogenomics Journal (2014) 14, 176–181; doi:10.1038/tpj.2013.12; published online 2 April 2013 Keywords: obsessive-compulsive disorder (OCD); pharmacogenetics; CYP2D6; CYP2C19; treatment response INTRODUCTION OCD is widely accepted as having strong genetic influence, with Obsessive-compulsive disorder (OCD) occurs in approximately two replicated findings reported for the glutamate transporter gene percent of the population1 and is characterized by a broad variety SLC1A1 and several serotonergic, dopaminergic and other 11 of obsessions and/or compulsions causing significant distress for candidate genes. There is growing interest in looking beyond the patient. Treatment options generally viewed as first-line susceptibility loci in psychiatry; for example, in major depression treatment include psychotherapy (cognitive behavioral therapy), disorder there is increasing evidence for impact of genetic factors and selective serotonin reuptake inhibitors.2 Although showing a on treatment response to antidepressants. Among the numerous similar success rate, the tricyclic antidepressant clomipramine has pharmacogenetic candidate genes implicated in treatment been associated with higher rates of adverse events during the response in depression studies are HTR2A, encoding serotonin treatment,3 and thus is usually regarded as a second line 2A receptors, the serotonin transporter gene SLC6A4, the gene alternative. Other strategies include antidepressants with encoding brain-derived neurotrophic factor, BDNF, TPH1 and TPH2, 12–15 different mechanisms of action, such as venlafaxine, mirtazapine encoding tryptophan hydroxylase 1 and 2 respectively. In or second-generation antipsychotics. Despite this broad variety of OCD, a very small number of pharmacogenetic studies have been available pharmacological options, only 40–60% of patients performed. Promising findings have been obtained in several show a sufficient treatment response.4,5 In OCD, higher dosages genes implicated in depression including HTR2A, SLC6A4, BDNF and longer treatment duration are required6 as compared with and COMT, encoding catechol-o-methyltransferase, the enzyme depressive disorders to achieve optimal response. There is no responsible for breaking down catecholamines. However, these standardized definition of response and remission in OCD, few studies have been underpowered and have delivered 16 although various groups have proposed reductions in the inconsistent results, supporting the need for further research. scores on the Yale-Brown Obsessive-Compulsive Scale or the Major candidates of interest for pharmacogenetic research are Clinical Global Impression-Improvement Scale (CGI-I).7 Similarly, no the genes encoding enzymes participating in the metabolism of reliable factors to predict treatment response have been identified antidepressants. These are primarily in the cytochrome (CYP) P450 as yet. Among the clinical and demographic factors reported to be family, and include CYP1A2, CYP2C19, CYP2D6 and CYP3A4. associated with a poorer response to selective serotonin reuptake CYP2D6 is involved in the metabolism of most antidepressants, inhibitor treatment are: long duration of untreated illness, severity, and is primarily responsible for breakdown of amitriptyline, onset in childhood and specific predominant symptoms such as venlafaxine, fluoxetine and paroxetine among others. This enzyme hoarding and symmetry.7 Besides these clinical factors, functional also contributes to the metabolism of other antidepressants such neuroimaging studies have demonstrated that normalization of as citalopram, duloxetine and mirtazapine. CYP2C19 mainly the observed increased activity in the cortico-striato-thalamo- metabolizes the antidepressants citalopram, escitalopram and cortical circuit of OCD patients is associated with successful amitriptyline17 and contributes to the metabolism of sertraline.18 treatment.8–10 CYP enzymes are highly variable in their activity, which is 1Department of Neuroscience, Neurogenetics Section, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; 2Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada and 3Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Correspondence: Dr MA Richter, Department of Psychiatry, Sunnybrook Health Sciences Centre, FG42, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. E-mail: [email protected] 4Co-senior authorship. Received 11 September 2012; revised 29 January 2013; accepted 4 February 2013; published online 2 April 2013 CYP genes and antidepressant response EJ Brandl et al 177 influenced by genetic variation, as well as by environmental factors ‘marked’ or ‘severe side effects’ were assigned to our ‘significant side and medication intake. Numerous allele variants, deletions effects’ group. As with analysis of response, we also investigated overall and duplications have been identified in CYP2D6, located on tolerance to medications in individuals who recalled multiple medication chromosome 22, and lead to reduced, absent or increased enzyme trials, grouping them depending on whether they reported significant side X activity (for an overview, see http://www.cypalleles.ki.se/cyp2d6.htm). effects to 50% oro50% of drugs tried. All patients gave their written informed consent. The procedures were in Individuals are typically classified as ultrarapid metabolizer (UM) with accordance with the institutional ethics guidelines and the declaration more than two active alleles, extensive metabolizer (EM) with one or of Helsinki. two active alleles, intermediate metabolizer (IM) with one or two alleles with reduced activity or poor metabolizer (PM) when no active Genotyping alleles are present. A similar classification can be undertaken for the CYP2C19 enzyme, encoded by the CYP2C19 gene, which is located Genomic DNA was purified from whole blood samples using a standard nonenzymatic method (described previously in Lahiri and Nurnberger32). on chromosome 10. Genotyping for CYP2D6*3 (rs35742686), *4 (rs3892097), *10 (rs1065852), The influence of impaired or elevated CYP2D619–25 and 26,27 *17 (rs28371706), *41 (rs28371725) and CYP2C19*2 (rs4244285), *3 CYP2C19 activity on plasma levels of different antidepressants (rs4986893) and *17 (rs12248560) was performed using predesigned has been demonstrated repeatedly. Therefore, an impact on treat- TaqMan SNP genotyping assays by Applied Biosystems, Foster City, CA, ment response to antidepressants seems highly likely. However, the USA. Copy number variants including the deletion (*5) and multiplications influence of CYP2D6 and CYP2C19 gene variation on treatment of CYP2D6 were determined using the copy number variant assay and response in OCD has not been extensively investigated. One study28 CopyCaller Version 1.0 (Applied Biosystems). Two independent researchers reported no association between the presence of four different confirmed the genotype calling and 5% of the sample was regenotyped alleles with reduced CYP2D6 activity with treatment response to with 100% concordance. Subjects for whom genotype status could not be called were excluded from the analyses. paroxetine or venlafaxine. In contrast, in a pilot study by our 29 Prediction of CYP2D6 PM, IM, EM or UM metabolizer status followed group, we found evidence for a worse treatment response in criteria based on the expected enzyme activity of the alleles, with *1 being patients with non-extensive (reduced or enhanced) CYP2D6 activity. fully active, *3,*4 and *5 leading to no enzyme activity and *10, *17 and To extend our previous pilot study and to further investigate the *41 leading to reduced activity. For CYP2C19, the predicted enzyme influence of predicted CYP2D6 and CYP2C19 metabolizer status on antidepressant response to in OCD, we have now performed an association study in a larger sample of OCD patients. Table 1. Basic demographic and clinical data of the study population (N ¼ 184) given as N or mean þ / À s.d. Gender (male: female) 71:113 MATERIALS AND METHODS Subjects Ethnicity European
Recommended publications
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Pgx - Cytochrome P450 2C19 (CYP2C19)
    PGx - Cytochrome P450 2C19 (CYP2C19) This assay is used to identify patients who may be at risk for altered metabolism of drugs that are modified by CYP2C19. Cytochrome P450 (CYP) isozyme 2C19 is responsible for phase I metabloism of about 40% of drugs including: clopidogrel, phenytoin, diazepam, R-warfarin, tamoxifen, some antidepressants, proton pump inhibitors, and antimalarials. Testing Method and Background This test utilizes the eSensor® 2C19 Genotyping Test is an in vitro diagnostic for the detection and genotyping a panel of variants involved with enzyme metabolism using isolated genomic DNA. The eSensor® technology uses a solid-phase electrochemical method for determining the genotyping status. The eSensor® 2C19 Genotyping Test is for research use only (RUO). CYP2C19 drug metabolism varies among individuals depending on specific genotype. The CYP2 family has many single- nucleotide polymorphisms (SNPs). CYP2C19 gene is located on chromosome 10q23.33 and is highly polymorphic, which can lead to large individual variation in CYP2C19 enzyme activity and related drug response phenotypes and/or undesired adverse drug events. Specifically, the CYP2C19 gene has more than 34 variant alleles identified, which in turn affects the pharmacokinetics of many drugs. Highlights of PGx - Cytochrome P450 2C19 (CYP2C19) Targeted Region CYP2C19: Detects 11 variants/polymorphisms 681G>A (*2) 636G>A (*3) 1A>G (*4) 1297C>T (*5) 395G>A (*6) 19294T>A (*7) 358T>C (*8) 431G>A (*9) 680C>T (*10) 1228C>T (*13) -806C>T (*17) Ordering Information Get started
    [Show full text]
  • Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2018/01/17/dmd.117.078428.DC1 1521-009X/46/4/367–379$35.00 https://doi.org/10.1124/dmd.117.078428 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:367–379, April 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans s Timothy Wong, Zhican Wang, Brian D. Chapron, Mizuki Suzuki, Katrina G. Claw, Chunying Gao, Robert S. Foti, Bhagwat Prasad, Alenka Chapron, Justina Calamia, Amarjit Chaudhry, Erin G. Schuetz, Ronald L. Horst, Qingcheng Mao, Ian H. de Boer, Timothy A. Thornton, and Kenneth E. Thummel Departments of Pharmaceutics (T.W., Z.W., B.D.C., M.S., K.G.C., C.G., B.P., Al.C., J.C., Q.M., K.E.T.), Medicine and Kidney Research Institute (I.H.d.B.), and Biostatistics (T.A.T.), University of Washington, Seattle, Washington; Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., South San Francisco, California (Z.W.); Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Cambridge, Massachusetts (R.S.F.); St. Jude Children’s Research Hospital, Memphis, Tennessee Downloaded from (Am.C., E.G.S.); and Heartland Assays LLC, Ames, Iowa (R.L.H.) Received September 1, 2017; accepted January 10, 2018 ABSTRACT dmd.aspetjournals.org Metabolism of 25-hydroxyvitamin D3 (25OHD3) plays a central role in with the rates of dehydroepiandrosterone sulfonation. Further analysis regulating the biologic effects of vitamin D in the body.
    [Show full text]
  • Frequencies of Clinically Important CYP2C19 and CYP2D6 Alleles Are Graded Across Europe
    European Journal of Human Genetics (2020) 28:88–94 https://doi.org/10.1038/s41431-019-0480-8 ARTICLE Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe 1,2 2 1 Jelena Petrović ● Vesna Pešić ● Volker M. Lauschke Received: 15 March 2019 / Revised: 3 July 2019 / Accepted: 17 July 2019 / Published online: 29 July 2019 © The Author(s) 2019. This article is published with open access Abstract CYP2C19 and CYP2D6 are important drug-metabolizing enzymes that are involved in the metabolism of around 30% of all medications. Importantly, the corresponding genes are highly polymorphic and these genetic differences contribute to interindividual and interethnic differences in drug pharmacokinetics, response, and toxicity. In this study we systematically analyzed the frequency distribution of clinically relevant CYP2C19 and CYP2D6 alleles across Europe based on data from 82,791 healthy individuals extracted from 79 original publications and, for the first time, provide allele confidence intervals for the general population. We found that frequencies of CYP2D6 gene duplications showed a clear South-East to North- West gradient ranging from <1% in Sweden and Denmark to 6% in Greece and Turkey. In contrast, an inverse distribution was observed for the loss-of-function alleles CYP2D6*4 and CYP2D6*5. Similarly, frequencies of the inactive CYP2C19*2 allele were graded from North-West to South-East Europe. In important contrast to previous work we found that the increased activity allele CYP2C19*17 was most prevalent in Central Europe (25–33%) with lower prevalence in Mediterranean-South Europeans (11–24%). In summary, we provide a detailed European map of common CYP2C19 and CYP2D6 variants and find that frequencies of the most clinically relevant alleles are geographically graded reflective of Europe’s migratory history.
    [Show full text]
  • Pharmacogenomic Characterization in Bipolar Spectrum Disorders
    pharmaceutics Review Pharmacogenomic Characterization in Bipolar Spectrum Disorders Stefano Fortinguerra 1,2 , Vincenzo Sorrenti 1,2,3 , Pietro Giusti 2, Morena Zusso 2 and Alessandro Buriani 1,2,* 1 Maria Paola Belloni Center for Personalized Medicine, Data Medica Group (Synlab Limited), 35131 Padova, Italy; [email protected] (S.F.); [email protected] (V.S.) 2 Department of Pharmaceutical & Pharmacological Sciences, University of Padova, 35131 Padova, Italy; [email protected] (P.G.); [email protected] (M.Z.) 3 Bendessere™ Study Center, Solgar Italia Multinutrient S.p.A., 35131 Padova, Italy * Correspondence: [email protected] Received: 25 November 2019; Accepted: 19 December 2019; Published: 21 December 2019 Abstract: The holistic approach of personalized medicine, merging clinical and molecular characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily spreading in clinical practice. Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression. Patients misdiagnosed as depressed are often initially prescribed serotonergic antidepressants, a treatment that can exacerbate a previously unrecognized bipolar condition. Thanks to the use of the patient’s genomic profile, it is possible to recognize such risk and at the same time characterize specific genetic assets specifically associated with bipolar spectrum disorder, as well as with the individual response to the various therapeutic options. This provides the basis for molecular diagnosis and the definition of pharmacogenomic profiles, thus guiding therapeutic choices and allowing a safer and more effective use of psychotropic drugs. Here, we report the pharmacogenomics state of the art in bipolar disorders and suggest an algorithm for therapeutic regimen choice.
    [Show full text]
  • Cytochrome P450 2C19 Loss-Of-Function Polymorphism Is Associated with an Increased Treatment-Related Mortality in Patients Undergoing Allogeneic Transplantation
    Bone Marrow Transplantation (2007) 40, 659–664 & 2007 Nature Publishing Group All rights reserved 0268-3369/07 $30.00 www.nature.com/bmt ORIGINAL ARTICLE Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation AH Elmaagacli, M Koldehoff, NK Steckel, R Trenschel, H Ottinger and DW Beelen Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany The polymorphic gene expression of CYP2C19 causes characterized enzymes with a large number of genetic individual variability in drug metabolism and thereby in polymorphisms is cytochrome P450 (CYP) 2C19.1 Pre- pharmacologic and toxicologic responses. We genotyped vious studies on CYP2C19 using probe drugs such as 286 patients and their donors for the CYP2C19 gene who S-mephenytoin showed that individuals could be classified underwent allogeneic transplantation for various diseases into three different groups: poor metabolizers (PMs), and analyzed their outcome. Patients were classified as: intermediate metabolizers (IMs) and extensive metabolizers poor metabolizers (PMs; 3.1%), intermediate metaboli- (EMs). PMs have a genetically determined absence of active zers (IMs; 24.5%) and extensive metabolizers (EMs; enzymes, which is the cause for a slower metabolism of 72.5%). Patients genotyped as PMs had significant higher active drugs and is associated with prolonged side effects.1 hepato- and nephrotoxicities compared to IMs or EMs. If prodrugs are applied, the metabolism in their active form Maximum bilirubin and serum creatinine levels measured is delayed and reduced effectiveness may occur. Among the after transplant were approximately twofold higher than drugs which are metabolized by CYP2C19 enzymes are those of EMs or IMs.
    [Show full text]
  • Methotrexate Induces Hyperplasia of Enterochromaffin
    112 BPB Reports 4, 112-115 (2021) Vol. 4, No. 4 Report Methotrexate Induces Hyperplasia of Enterochromaffin Cells in Mouse Jejunum Takuji Machida,*,a Airi Tanaka,a Megumi Kobayashi,a Kohei Imai,a Masahiko Hirafuji,a,b and Kenji Iizukaa aDepartment of Pharmacological Sciences, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan; bPresent address: School of Health Sciences, Iryo Sosei University, 5-5-1 Chuodai Iino, Iwaki, Fukushima 970-8551, Japan Received May 12, 2021; Accepted July 26, 2021 5-Hydroxytryptamine (5-HT) is synthesized by L-tryptophan hydroxylase (TPH) and is stored mainly in enterochromaffin cells of the mucosal epithelium. We previously reported that administration of methotrex- ate, an anticancer agent, to rats caused hyperplasia of enterochromaffin cells, and nitric oxide (NO) might be involved in the underlying mechanism. The aim of this study was to clarify the effect of methotrexate on hyper- plasia of enterochromaffin cells in mice. C57BL/6J mice were intraperitoneally injected with methotrexate or saline as a control. Methotrexate caused an increase in the number of TPH-expressing cells (i.e., enterochromaf- fin cells) in the jejunum. Methotrexate also increased inducible, but not constitutive, NOS mRNA expression. Our results indicate that methotrexate potentiates 5-HT synthesis in mice, as we previously found in rats. Key words methotrexate, intestine, 5-hydroxytriptamine, inducible nitric oxide synthase INTRODUCTION the effects of methotrexate are similar to those previously found in rats.4,6) The use of high doses of methotrexate, an anti-cancer drug, is associated with gastrointestinal damage, which leads to mal- MATERIALS AND METHODS absorption, diarrhea, and weight loss.1,2) In addition, metho- trexate causes moderate emesis in humans and experimental Materials Methotrexate was obtained from Pfizer Co., Ltd.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • Electronic Supplementary Material (ESI) for Metallomics
    Electronic Supplementary Material (ESI) for Metallomics. This journal is © The Royal Society of Chemistry 2018 Uniprot Entry name Gene names Protein names Predicted Pattern Number of Iron role EC number Subcellular Membrane Involvement in disease Gene ontology (biological process) Id iron ions location associated 1 P46952 3HAO_HUMAN HAAO 3-hydroxyanthranilate 3,4- H47-E53-H91 1 Fe cation Catalytic 1.13.11.6 Cytoplasm No NAD biosynthetic process [GO:0009435]; neuron cellular homeostasis dioxygenase (EC 1.13.11.6) (3- [GO:0070050]; quinolinate biosynthetic process [GO:0019805]; response to hydroxyanthranilate oxygenase) cadmium ion [GO:0046686]; response to zinc ion [GO:0010043]; tryptophan (3-HAO) (3-hydroxyanthranilic catabolic process [GO:0006569] acid dioxygenase) (HAD) 2 O00767 ACOD_HUMAN SCD Acyl-CoA desaturase (EC H120-H125-H157-H161; 2 Fe cations Catalytic 1.14.19.1 Endoplasmic Yes long-chain fatty-acyl-CoA biosynthetic process [GO:0035338]; unsaturated fatty 1.14.19.1) (Delta(9)-desaturase) H160-H269-H298-H302 reticulum acid biosynthetic process [GO:0006636] (Delta-9 desaturase) (Fatty acid desaturase) (Stearoyl-CoA desaturase) (hSCD1) 3 Q6ZNF0 ACP7_HUMAN ACP7 PAPL PAPL1 Acid phosphatase type 7 (EC D141-D170-Y173-H335 1 Fe cation Catalytic 3.1.3.2 Extracellular No 3.1.3.2) (Purple acid space phosphatase long form) 4 Q96SZ5 AEDO_HUMAN ADO C10orf22 2-aminoethanethiol dioxygenase H112-H114-H193 1 Fe cation Catalytic 1.13.11.19 Unknown No oxidation-reduction process [GO:0055114]; sulfur amino acid catabolic process (EC 1.13.11.19) (Cysteamine
    [Show full text]
  • PGX CYP2C19 Genotyping
    PGX CYP2C19 Genotyping For detection of CYP2C19 variants affecting drug metabolism Clinical Background CYP2C19 isan isoenzyme of the CYP450 superfamily that metabolizes and eliminates common prescription drugs, including anti-convulsants, anti-depressants, proton pump inhibitors, and antithrombotics (clopidogrel/Plavix®), as well as anti-malaria and anti-ulcer drugs. Metabolizer phenotypes can be predicted by the CYP2C19 genotype The clinical impact of the CYP2C19 genotype is influenced by whether a drug is activated or inactivated by CYP2C19, involvement of other metabolic pathways, and other non-genetic factors (eg, other medications) Epidemiology CYP2C19 variant frequency is ethnicity dependent. The poor metabolizer phenotype (caused by two non-functional CYP2C19 alleles) is present in 4% of Caucasians, 5% of African Americans, and up to 25% of Asians. Genetics The CYP2C19 gene has nine exons and is located on chromosome 10q23.33. Inheritance is autosomal recessive. Penetrance is drug-dependent. Indications for Ordering Pre-therapeutic testing to identify individuals who should avoid, or may require unconventional doses of medications metabolized by CYP2C19. Interpretation If no CYP2C19 variants are detected, this suggests *1 allele and normal enzymatic activity. If one decreased functional or non-functional CYP2C19 variant is detected, intermediate-to- normal CYP2C19 enzymatic activity is predicted. If two non-functional variants are present on opposite alleles, this predicts low CYP2C19 enzymatic activity and a poor metabolizer phenotype. Indiana University School of Medicine Division of Diagnostic Genomics - Pharmacogenomics Laboratory 975 West Walnut Street, IB247 Indianapolis, IN. 46202-5251 Tel. 317-274-0143 Genotype results should be interpreted in context of the individual clinical situation. Consultation with a clinical pharmacy professional is recommended.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • The Genetics of Bipolar Disorder
    Molecular Psychiatry (2008) 13, 742–771 & 2008 Nature Publishing Group All rights reserved 1359-4184/08 $30.00 www.nature.com/mp FEATURE REVIEW The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions A Serretti and L Mandelli Institute of Psychiatry, University of Bologna, Bologna, Italy Bipolar disorder (BP) is a complex disorder caused by a number of liability genes interacting with the environment. In recent years, a large number of linkage and association studies have been conducted producing an extremely large number of findings often not replicated or partially replicated. Further, results from linkage and association studies are not always easily comparable. Unfortunately, at present a comprehensive coverage of available evidence is still lacking. In the present paper, we summarized results obtained from both linkage and association studies in BP. Further, we indicated new potential interesting genes, located in genome ‘hot regions’ for BP and being expressed in the brain. We reviewed published studies on the subject till December 2007. We precisely localized regions where positive linkage has been found, by the NCBI Map viewer (http://www.ncbi.nlm.nih.gov/mapview/); further, we identified genes located in interesting areas and expressed in the brain, by the Entrez gene, Unigene databases (http://www.ncbi.nlm.nih.gov/entrez/) and Human Protein Reference Database (http://www.hprd.org); these genes could be of interest in future investigations. The review of association studies gave interesting results, as a number of genes seem to be definitively involved in BP, such as SLC6A4, TPH2, DRD4, SLC6A3, DAOA, DTNBP1, NRG1, DISC1 and BDNF.
    [Show full text]